UK markets closed

Forte Biosciences, Inc. (FBRX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7141+0.0141 (+2.01%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 25.99M
Enterprise value -11.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.74
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.34

Trading information

Stock price history

Beta (5Y monthly) 1.65
52-week change 3-34.91%
S&P500 52-week change 322.38%
52-week high 31.1100
52-week low 30.3800
50-day moving average 30.7066
200-day moving average 30.6991

Share statistics

Avg vol (3-month) 332.79k
Avg vol (10-day) 313.25k
Shares outstanding 536.39M
Implied shares outstanding 636.39M
Float 822.01M
% held by insiders 110.91%
% held by institutions 156.08%
Shares short (15 Apr 2024) 433.02k
Short ratio (15 Apr 2024) 41.36
Short % of float (15 Apr 2024) 40.10%
Short % of shares outstanding (15 Apr 2024) 40.09%
Shares short (prior month 15 Mar 2024) 442.18k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 316 Jun 2020
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 316 Jun 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-50.15%
Return on equity (ttm)-84.92%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -32.48M
Net income avi to common (ttm)-31.48M
Diluted EPS (ttm)-1.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)37.12M
Total cash per share (mrq)1.02
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)10.45
Book value per share (mrq)0.97

Cash flow statement

Operating cash flow (ttm)-28.71M
Levered free cash flow (ttm)-17.4M